Allogene Therapeutics(ALLO)
$0.90-0.03 (-3.33%)
ALLO
Allogene Therapeutics financials statements
$0.90
At close:-0.03 (-3.33%)
Want to see ALLO full AI Analyst Report?
Allogene Therapeutics (ALLO) Ratios
1,853 Followers
Allogene Therapeutics Ratios
ALLO's free cash flow for Q3 2026 was $-36.14M. For the 2026 fiscal year, ALLO's free cash flow was decreased by $-25.00K and operating cash flow was $-36.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.93 | 8.54 | 12.38 | 9.84 | 9.84 |
| Quick Ratio | 7.93 | 8.54 | 12.38 | 9.84 | 9.84 |
| Cash Ratio | 1.59 | 2.12 | 2.24 | 1.15 | 3.62 |
| Solvency Ratio | -1.45 | -1.93 | -2.40 | -2.11 | -1.37 |
| Operating Cash Flow Ratio | -4.59 | -5.64 | -6.41 | -4.10 | -3.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 134.39M | $ 176.85M | $ 328.51M | $ 374.13M | $ 345.69M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.20 | 0.17 | 0.15 | 0.12 | 0.07 |
| Debt-to-Equity Ratio | 0.28 | 0.21 | 0.19 | 0.15 | 0.08 |
| Debt-to-Capital Ratio | 0.22 | 0.18 | 0.16 | 0.13 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.42 | 1.30 | 1.25 | 1.23 | 1.14 |
| Debt Service Coverage Ratio | -165.07 | -1346.80 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -192.50 | -1509.39 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.38 | 0.47 | 0.61 | 0.71 | 0.54 |
| Net Debt to EBITDA | -0.18 | -0.06 | -0.04 | -0.12 | 0.59 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 100.00% | -9063.46% | 100.00% |
| EBIT Margin | 0.00% | -1168027.27% | -344489.47% | -215087.18% | -157.94% |
| EBITDA Margin | 0.00% | -1106031.82% | -329543.16% | -205923.72% | -148.78% |
| Operating Profit Margin | 0.00% | -1241813.64% | -344986.32% | -215087.18% | -157.94% |
| Pretax Profit Margin | 0.00% | -1168850.00% | -344489.47% | -218214.10% | -159.57% |
| Net Profit Margin | 0.00% | -1170863.64% | -344489.47% | -218214.10% | -159.57% |
| Continuous Operations Profit Margin | 0.00% | -1170863.64% | -344489.47% | -218214.10% | -159.57% |
| Net Income Per EBT | 100.00% | 100.17% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.25% | 94.12% | 99.86% | 101.45% | 101.03% |
| Return on Assets (ROA) | -45.90% | -46.94% | -50.91% | -41.43% | -17.32% |
| Return on Equity (ROE) | -65.25% | -61.01% | -63.89% | -51.05% | -19.68% |
| Return on Capital Employed (ROCE) | -53.97% | -53.24% | -54.10% | -43.70% | -17.97% |
| Return on Invested Capital (ROIC) | -52.84% | -52.47% | -53.51% | -43.36% | -17.91% |
| Return on Tangible Assets | -45.90% | -46.94% | -50.91% | -41.43% | -17.32% |
| Earnings Yield | -63.15% | -62.08% | -64.97% | -37.81% | -8.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.01 | 0.06 | 0.00 | 0.00 |
| Payables Turnover | 2.89 | 0.00 | 0.00 | 1.03 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 |
| Cash Conversion Cycle | -126.11 | 31522.73 | 6531.58 | -354.66 | 0.00 |
| Days of Sales Outstanding | 0.00 | 31522.73 | 6531.58 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 126.11 | 0.00 | 0.00 | 354.66 | 0.00 |
| Operating Cycle | 0.00 | 31522.73 | 6531.58 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.68 | -1.03 | -1.51 | -1.54 | -1.36 |
| Free Cash Flow Per Share | -0.68 | -1.03 | -1.52 | -1.58 | -1.52 |
| Dividend Paid and CapEx Coverage Ratio | -386.65 | -288.62 | -156.82 | -42.48 | -8.62 |
| Capital Expenditure Coverage Ratio | -386.65 | -288.62 | -156.82 | -42.48 | -8.62 |
| Operating Cash Flow Coverage Ratio | -1.79 | -2.21 | -2.50 | -2.18 | -2.53 |
| Operating Cash Flow to Sales Ratio | 0.00 | -9104.55 | -2502.45 | -1413.58 | -1.62 |
| Free Cash Flow Yield | -49.51% | -48.44% | -47.49% | -25.07% | -10.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.57 | -1.61 | -1.54 | -2.64 | -11.13 |
| Price-to-Sales (P/S) Ratio | 0.00 | 18861.34 | 5302.65 | 5771.76 | 17.76 |
| Price-to-Book (P/B) Ratio | 1.03 | 0.98 | 0.98 | 1.35 | 2.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.02 | -2.06 | -2.11 | -3.99 | -9.82 |
| Price-to-Operating Cash Flow Ratio | -2.03 | -2.07 | -2.12 | -4.08 | -10.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | 0.04 | 0.13 | -0.03 | 0.31 |
| Enterprise Value Multiple | -1.88 | -1.77 | -1.65 | -2.92 | -11.35 |
| Enterprise Value | 333.82M | 430.49M | 515.72M | 939.61M | 1.93B |
| EV to EBITDA | -1.88 | -1.77 | -1.65 | -2.92 | -11.35 |
| EV to Sales | 0.00 | 19567.62 | 5428.61 | 6023.17 | 16.88 |
| EV to Free Cash Flow | -2.23 | -2.14 | -2.16 | -4.16 | -9.34 |
| EV to Operating Cash Flow | -2.24 | -2.15 | -2.17 | -4.26 | -10.42 |
| Tangible Book Value Per Share | 1.33 | 2.17 | 3.26 | 4.66 | 6.81 |
| Shareholders’ Equity Per Share | 1.33 | 2.17 | 3.26 | 4.66 | 6.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 |
| Net Income Per Share | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 1.00 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 8740.86 | 2556.99 | 1643.51 | 1.93 |
| SG&A to Revenue | 0.00 | 2963.86 | 754.45 | 508.37 | 0.65 |
| Stock-Based Compensation to Revenue | 0.00 | 2351.95 | 694.22 | 535.90 | 0.71 |
| Income Quality | 0.78 | 0.78 | 0.73 | 0.66 | 0.72 |
Currency in USD
